EP1917034A4 - Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier - Google Patents

Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier

Info

Publication number: EP1917034A4
Authority: EP; European Patent Office
Prior art keywords: antigen; methods; same; specific cytotoxic; cytotoxic conjugate
Prior art date: 2005-08-22
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP05788869A

Other languages

German (de)

English (en)

Other versions

EP1917034A1 (fr

Inventor

Gillian Payne

Philip Chun

Daniel Tavares

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Immunogen Inc

Original Assignee

Immunogen Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-08-22

Filing date

2005-08-22

Publication date

2009-04-29

2005-08-22 Application filed by Immunogen Inc filed Critical Immunogen Inc

2008-05-07 Publication of EP1917034A1 publication Critical patent/EP1917034A1/fr

2009-04-29 Publication of EP1917034A4 publication Critical patent/EP1917034A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6875—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin
- A61K47/6877—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody being a hybrid immunoglobulin the antibody being an immunoglobulin containing regions, domains or residues from different species
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
- C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
- C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

EP05788869A 2005-08-22 2005-08-22 Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier Withdrawn EP1917034A4 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
PCT/US2005/030115 WO2007024222A1 (fr)	2005-08-22	2005-08-22	Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier

Publications (2)

Publication Number	Publication Date
EP1917034A1 EP1917034A1 (fr)	2008-05-07
EP1917034A4 true EP1917034A4 (fr)	2009-04-29

Family

ID=37771883

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP05788869A Withdrawn EP1917034A4 (fr)	2005-08-22	2005-08-22	Conjugue cytotoxique specifique de l'antigene ca6 et methodes d'utilisation de ce dernier

Country Status (13)

Country	Link
EP (1)	EP1917034A4 (fr)
JP (1)	JP2009504193A (fr)
CN (1)	CN101242855A (fr)
AU (1)	AU2005335743A1 (fr)
BR (1)	BRPI0520509A2 (fr)
CA (1)	CA2615761A1 (fr)
EA (1)	EA020130B9 (fr)
EC (1)	ECSP088241A (fr)
HK (1)	HK1211965A1 (fr)
IL (2)	IL189628A0 (fr)
MX (1)	MX2008002607A (fr)
NO (1)	NO20080893L (fr)
WO (1)	WO2007024222A1 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9353150B2 (en)	2012-12-04	2016-05-31	Massachusetts Institute Of Technology	Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
US9844607B2 (en)	2013-02-05	2017-12-19	Sanofi	Immuno imaging agent for use with antibody-drug conjugate therapy
JP6605331B2 (ja) *	2013-02-05	2019-11-13	サノフイ	抗体−薬物複合体治療での使用のための免疫造影剤
SG11201506053VA (en) *	2013-02-05	2015-08-28	Sanofi Sa	Immuno imaging agent for use with antibody-drug conjugate therapy
US9989524B2 (en)	2013-02-05	2018-06-05	Sanofi	Immuno imaging agent for use with antibody-drug conjugate therapy
KR20160035600A (ko) *	2013-08-02	2016-03-31	사노피	고형 종양의 치료를 위한 항-muc1 메이탄시노이드 면역접합체 항체의 용도
JP2017526682A (ja)	2014-09-02	2017-09-14	イミュノジェン，インコーポレイテッド	抗体薬物複合体組成物の製剤化方法
EP3189057A1 (fr)	2014-09-03	2017-07-12	ImmunoGen, Inc.	Dérivés de benzodiazépine cytotoxique
PT3189056T (pt)	2014-09-03	2020-09-04	Immunogen Inc	Derivados citotóxicos de benzodiazepina
DK3380525T3 (da)	2015-11-25	2024-01-29	Immunogen Inc	Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf
WO2017197045A1 (fr)	2016-05-11	2017-11-16	Movassaghi Mohammad	Synthèse totale convergente et énantiosélective d'analogues de la communesine
AU2018229277B2 (en)	2017-02-28	2025-03-20	Immunogen, Inc.	Maytansinoid derivatives with self-immolative peptide linkers and conjugates thereof
US20180346488A1 (en)	2017-04-20	2018-12-06	Immunogen, Inc.	Cytotoxic benzodiazepine derivatives and conjugates thereof
WO2018209239A1 (fr)	2017-05-11	2018-11-15	Massachusetts Institute Of Technology	Dérivés d'agélastatine puissants en tant que modulateurs de l'invasion et de la métastase du cancer
US10640508B2 (en)	2017-10-13	2020-05-05	Massachusetts Institute Of Technology	Diazene directed modular synthesis of compounds with quaternary carbon centers
TWI827575B (zh)	2017-12-28	2024-01-01	美商伊繆諾金公司	苯二氮平衍生物
US11535634B2 (en)	2019-06-05	2022-12-27	Massachusetts Institute Of Technology	Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (fr)	2021-02-24	2022-09-01	Massachusetts Institute Of Technology	Dérivés d'himastatine, leurs procédés de préparation et leurs utilisations

Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040241174A1 (en) *	2003-05-14	2004-12-02	Immunogen, Inc.	Drug conjugate composition

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6596503B1 (en) *	2000-08-18	2003-07-22	East Carolina University	Monoclonal antibody DS6, tumor-associated antigen CA6, and methods of use thereof
ATE496944T1 (de) *	2003-07-21	2011-02-15	Immunogen Inc	Ca6-antigenspezifisches zytotoxisches konjugat und verfahren zu dessen anwendung

2005
- 2005-08-22 CA CA002615761A patent/CA2615761A1/fr not_active Abandoned
- 2005-08-22 MX MX2008002607A patent/MX2008002607A/es not_active Application Discontinuation
- 2005-08-22 EP EP05788869A patent/EP1917034A4/fr not_active Withdrawn
- 2005-08-22 CN CNA200580051368XA patent/CN101242855A/zh active Pending
- 2005-08-22 EA EA200800642A patent/EA020130B9/ru not_active IP Right Cessation
- 2005-08-22 BR BRPI0520509-3A patent/BRPI0520509A2/pt not_active Application Discontinuation
- 2005-08-22 JP JP2008527882A patent/JP2009504193A/ja not_active Withdrawn
- 2005-08-22 WO PCT/US2005/030115 patent/WO2007024222A1/fr not_active Ceased
- 2005-08-22 AU AU2005335743A patent/AU2005335743A1/en not_active Abandoned
2008
- 2008-02-20 IL IL189628A patent/IL189628A0/en unknown
- 2008-02-20 NO NO20080893A patent/NO20080893L/no not_active Application Discontinuation
- 2008-03-05 EC EC2008008241A patent/ECSP088241A/es unknown
2015
- 2015-05-13 IL IL238798A patent/IL238798A0/en unknown
- 2015-12-31 HK HK15112923.0A patent/HK1211965A1/xx unknown

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040241174A1 (en) *	2003-05-14	2004-12-02	Immunogen, Inc.	Drug conjugate composition

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
CHUN P ET AL: "POTENT ANTI-CANCER ACTIVITY OF DS6-DM1, AN ANTIBODY-DRUG CONJUGATE TARGETING A MUC1 GLYCOTOPE ON OVARIAN, BREAST AND PANCREATIC CARCINOMAS", CLINICAL CANCER RESEARCH, THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 9, no. SUPPL. 16, 1 December 2003 (2003-12-01), pages 6186S,ABSTRACTB205, XP008069628, ISSN: 1078-0432 *
KEARSE K P ET AL: "MONOCLONAL ANTIBODY DS6 DETECTS A TUMOR-ASSOCIATED SIALOGLYCOTOPE EXPRESSED ON HUMAN SEROUS OVARIAN CARCINOMAS", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, UNITED STATES, SWITZERLAND, GERMANY, vol. 88, no. 88, 1 January 2000 (2000-01-01), pages 866 - 872, XP002907222, ISSN: 0020-7136 *
MACCALLUM R M ET AL: "Antibody-antigen interactions: Contact analysis and binding site topography", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 262, no. 5, 1 January 1996 (1996-01-01), pages 732 - 745, XP002242391, ISSN: 0022-2836, DOI: 10.1006/JMBI.1996.0548 *
RUDIKOFF S ET AL: "Single amino acid substitution altering antigen-binding specificity", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES (PNAS), NATIONAL ACADEMY OF SCIENCE, US, vol. 79, 1 March 1982 (1982-03-01), pages 1979 - 1983, XP007901436, ISSN: 0027-8424, DOI: 10.1073/PNAS.79.6.1979 *
See also references of WO2007024222A1 *
SMITH N L ET AL: "IMMUNOHISTOCHEMICAL DISTRIBUTION OF TUMOR-ASSOCIATED ANTIGEN CA6 IN GYNECOLOGICAL NEOPLASMS AS DETECTED BY MONOCLONAL ANTIBODY DS6", INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, NEW YORK, NY, US, vol. 20, no. 20, 1 July 2001 (2001-07-01), pages 260 - 266, XP002907224, ISSN: 0277-1691 *
SMITH NL ET AL: "PATTERNS OF EXPRESSION OF THE DS6-GLYCOFORM OF MUC1 CORRELATES WITH KNOWN PROGNOSTIC INDICATORS IN BREAST CANCER", PROCEEDINGS OF THE ANNUAL MEETING OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, NEW YORK, NY, vol. 45, 1 January 2004 (2004-01-01), pages 239,ABSTRACT1051, XP001247901, ISSN: 0197-016X *

Also Published As

Publication number	Publication date
IL238798A0 (en)	2015-06-30
AU2005335743A1 (en)	2007-03-01
MX2008002607A (es)	2008-03-19
EA020130B9 (ru)	2014-10-30
IL189628A0 (en)	2008-06-05
NO20080893L (no)	2008-05-22
EP1917034A1 (fr)	2008-05-07
EA200800642A1 (ru)	2008-08-29
HK1211965A1 (en)	2016-06-03
CN101242855A (zh)	2008-08-13
BRPI0520509A2 (pt)	2009-05-12
WO2007024222A1 (fr)	2007-03-01
ECSP088241A (es)	2008-04-28
JP2009504193A (ja)	2009-02-05
CA2615761A1 (fr)	2007-03-01
EA020130B1 (ru)	2014-08-29

Publication	Publication Date	Title
IL238798A0 (en)	2015-06-30	Cytotoxic conjugate specific for ca6 antigen and methods for its use
EP1793803A4 (fr)	2009-09-23	Compositions de medicament a liberation soutenue pouvant etre implantees de facon appropriee
IL191759A0 (en)	2008-12-29	Ganaxolone formulations and methods for the making and use thereof
IL188964A0 (en)	2008-08-07	Sustained drug release composition
IL191941A0 (en)	2008-12-29	Conjugate vaccines
IL186521A0 (en)	2008-01-20	Nanoparticle-active ingredient conjugates
LT1912671T (lt)	2017-12-11	Vaisto konjugatai, turintys gliukoronido linkerį
ZAA200500075S (en)	2005-08-18	Prosthetic article
EP2043647A4 (fr)	2013-05-01	Formulations à libération contrôlée et procédés associés
IL222915A0 (en)	2012-12-31	Improved tuberculosis vaccines
EP1852420A4 (fr)	2011-06-15	Composé d indole et utilisation de celui-ci
PL1963369T3 (pl)	2013-10-31	Antagoniści IL-21
ZA200610204B (en)	2008-01-30	Irinotecan preparation
EP1976490A4 (fr)	2009-01-14	Comprimé à libération prolongée contenant du zaltoprofène et procédé de préparation dudit comprimé
IL185723A0 (en)	2008-01-06	Controlled release pharmaceutical compositions of liothyronine and methods of making and using the same
EP1802346A4 (fr)	2011-07-06	Composition pharmaceutique à libération prolongée
EP2097085A4 (fr)	2010-02-10	Matériaux et procédés thérapeutiques
HK1111621A (en)	2008-08-15	A ca6 antigen-specific cytotoxic conjugate and methods of using the same
ZA200800304B (en)	2009-08-26	A CA6 antigen-specific cytotoxic conjugate and methods of using the same
EP1810976A4 (fr)	2007-10-17	Dérivé de benzonaphthacèneglycoside et utilisation dudit dérivé
GB0610012D0 (en)	2006-06-28	Joint prosthesis
SI1915137T1 (sl)	2013-12-31	Pripravek z nadzorovanim sproĹˇÄŤanjem za peroralno dajanje
ZA200805298B (en)	2009-11-25	Conjugate vaccines
EP1946759A4 (fr)	2009-12-23	Agent thérapeutique contre la nausée et/ou le vomissement
ZA200509261B (en)	2006-07-26	Mechanical joint

Legal Events

Date	Code	Title	Description
2008-04-04	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2008-05-07	17P	Request for examination filed	Effective date: 20080125
2008-05-07	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR
2008-05-07	AX	Request for extension of the european patent	Extension state: AL BA HR MK YU
2008-08-15	REG	Reference to a national code	Ref country code: HK Ref legal event code: DE Ref document number: 1111621 Country of ref document: HK
2009-04-29	A4	Supplementary search report drawn up and despatched	Effective date: 20090326
2009-06-17	RAP1	Party data changed (applicant data changed or rights of an application transferred)	Owner name: IMMUNOGEN, INC.
2009-07-15	17Q	First examination report despatched	Effective date: 20090615
2012-05-25	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2012-06-27	18D	Application deemed to be withdrawn	Effective date: 20120110
2014-03-21	REG	Reference to a national code	Ref country code: HK Ref legal event code: WD Ref document number: 1111621 Country of ref document: HK